Impact of Coronavirus Disease 2019 Pandemic on the Epidemiology of Intravitreal Injections.

IF 1.2 Q3 OPHTHALMOLOGY Journal of Current Ophthalmology Pub Date : 2022-10-01 DOI:10.4103/joco.joco_253_22

Masoud Mirghorbani, Hamid Riazi-Esfahani, Fatemeh Bazvand, Mohammadreza Mehrabi Bahar, Mehdi Yaseri, Mohammad Zarei

{"title":"Impact of Coronavirus Disease 2019 Pandemic on the Epidemiology of Intravitreal Injections.","authors":"Masoud Mirghorbani, Hamid Riazi-Esfahani, Fatemeh Bazvand, Mohammadreza Mehrabi Bahar, Mehdi Yaseri, Mohammad Zarei","doi":"10.4103/joco.joco_253_22","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the epidemiologic pattern of intravitreal injections (IVIs) during Coronavirus Disease 2019 (COVID-19) pandemic.Methods: The records of patients receiving IVIs in two 12-month periods immediately before and after the beginning of the COVID-19 epidemic were included. Age, province of residency, indication, number of injections, and number of operating room (OR) visits were analyzed.Results: Compared to pre-COVID period, a 37.6% decrease in the number of patients receiving IVI in COVID period was seen (10518 vs. 6569). There was a parallel decrease in the number of OR visits (25590 vs. 15010: 41.4%) and injections (34508 vs. 19879: 42.4%). Regarding IVI indication, age-related macular degeneration (AMD) showed the highest decrease in IVI rate (46.3%) which was significantly higher than decrease in other indications (P < 0.001). Retinopathy of prematurity (ROP) patients showed no change after epidemic. Mean overall age in AMD group was the highest (67.7 ± 13.2 years) compared to other indication groups (excluding ROP) (P < 0.001); while the mean age of the other indications was not significantly different from each other (excluding ROP).Conclusions: COVID pandemic decreased the number of IVIs significantly. While previous studies suggested that the AMD patients had the highest risk of visual loss due to failure to receive IVIs in a timely manner, this very same group showed the highest decrease in the IVI number after pandemic. The health systems should devise strategies to protect this most vulnerable group of patients in future similar crises.","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/8c/JCO-34-442.PMC10170993.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joco.joco_253_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the epidemiologic pattern of intravitreal injections (IVIs) during Coronavirus Disease 2019 (COVID-19) pandemic.

Methods: The records of patients receiving IVIs in two 12-month periods immediately before and after the beginning of the COVID-19 epidemic were included. Age, province of residency, indication, number of injections, and number of operating room (OR) visits were analyzed.

Results: Compared to pre-COVID period, a 37.6% decrease in the number of patients receiving IVI in COVID period was seen (10518 vs. 6569). There was a parallel decrease in the number of OR visits (25590 vs. 15010: 41.4%) and injections (34508 vs. 19879: 42.4%). Regarding IVI indication, age-related macular degeneration (AMD) showed the highest decrease in IVI rate (46.3%) which was significantly higher than decrease in other indications (P < 0.001). Retinopathy of prematurity (ROP) patients showed no change after epidemic. Mean overall age in AMD group was the highest (67.7 ± 13.2 years) compared to other indication groups (excluding ROP) (P < 0.001); while the mean age of the other indications was not significantly different from each other (excluding ROP).

Conclusions: COVID pandemic decreased the number of IVIs significantly. While previous studies suggested that the AMD patients had the highest risk of visual loss due to failure to receive IVIs in a timely manner, this very same group showed the highest decrease in the IVI number after pandemic. The health systems should devise strategies to protect this most vulnerable group of patients in future similar crises.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2019冠状病毒病大流行对玻璃体内注射流行病学的影响

目的:探讨2019冠状病毒病(COVID-19)大流行期间玻璃体内注射(IVIs)的流行病学特征。方法:收集COVID-19疫情开始前后两个12个月内接受静脉注射的患者记录。分析年龄、居住省份、适应证、注射次数和手术室就诊次数。结果:与COVID前相比，COVID期间接受IVI的患者数量减少了37.6%(10518例对6569例)。手术室就诊次数(25590次vs. 15010次:41.4%)和注射次数(34508次vs. 19879次:42.4%)也有平行下降。在IVI适应症中，年龄相关性黄斑变性(AMD)的IVI率下降幅度最大(46.3%)，显著高于其他适应症的下降幅度(P < 0.001)。早产儿视网膜病变(ROP)流行后无明显变化。AMD组患者平均总年龄(67.7±13.2岁)高于其他适应症组(不含ROP) (P < 0.001);而其他适应症的平均年龄差异无统计学意义(不包括ROP)。结论:新冠肺炎疫情显著降低了静脉注射次数。虽然先前的研究表明，由于未能及时接受静脉注射，AMD患者视力丧失的风险最高，但同一组在大流行后静脉注射数量下降幅度最大。卫生系统应制定战略，在未来类似危机中保护这一最脆弱的患者群体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Current Ophthalmology OPHTHALMOLOGY-

CiteScore

2.50

自引率

6.70%

发文量

审稿时长

8 weeks

期刊介绍： Peer Review under the responsibility of Iranian Society of Ophthalmology Journal of Current Ophthalmology, the official publication of the Iranian Society of Ophthalmology, is a peer-reviewed, open-access, scientific journal that welcomes high quality original articles related to vision science and all fields of ophthalmology. Journal of Current Ophthalmology is the continuum of Iranian Journal of Ophthalmology published since 1969.